| Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. | |
| | |
MedLine Citation:
|
PMID: 22018679 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The global clinical and economic burden of type 2 diabetes is substantial. Recently, clinical trials with glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) have shown a multifactorial clinical profile with the potential to address many of the clinical needs of patients and reduce the burden of disease. OBJECTIVE: The goal of this study was to evaluate the long-term cost-effectiveness of once-daily liraglutide versus exenatide BID in patients with type 2 diabetes who failed to improve with metformin and/or sulfonylurea, based on the results of a previous clinical trial in 6 European countries (Switzerland, Denmark, Norway, Finland, the Netherlands, and Austria). METHODS: A validated computer simulation model of diabetes was used to predict life expectancy, quality-adjusted life years (QALYs), and incidence of diabetes-related complications in patients receiving liraglutide (1.8 mg once daily) or exenatide (10 μg BID). Baseline cohort characteristics and treatment effects were derived from the Liraglutide Effect and Action in Diabetes 6 trial. Country-specific complication costs were taken from published sources. Simulations were run over 40 years from third-party payer perspectives. Future costs and clinical benefits were discounted at country-specific discount rates. Sensitivity analyses were performed. RESULTS: Liraglutide was associated with improvements of 0.12 to 0.17 QALY and a reduced incidence of most diabetes-related complications versus exenatide in all settings. Evaluation of total direct medical costs (treatment plus complication costs) suggest that liraglutide was likely to cost between Euro (€) 1023 and €1866 more than exenatide over patients' lifetimes, leading to incremental cost-effectiveness ratios per QALY gained versus exenatide of: Switzerland, CHF (Swiss francs) 10,950 (€6902); Denmark, Danish krone [kr] 88,160 (€11,805); Norway, Norwegian krone [kr], 111,916 (€13,546); Finland, €8459; the Netherlands, €8119; and Austria, €8516. CONCLUSIONS: Long-term projections indicated that liraglutide was associated with benefits in life expectancy, QALYs, and reduced complication rates versus exenatide. Liraglutide was cost-effective from a health care payer perspective in Switzerland, Denmark, Norway, Finland, the Netherlands, and Austria. Clinicaltrials.gov identifier: NCT 00518882. |
| | |
Authors:
|
William J Valentine; Andrew J Palmer; Morten Lammert; Jakob Langer; Michael Brändle |
Related Documents
:
|
20432259 - Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. 10852599 - Regulation of glucose tolerance in patients after liver transplantation: impact of cycl... 15532719 - Altered mg2+ transport across liver plasma membrane from streptozotocin-treated rats. 11036799 - Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. 6142119 - Raised gamma glutamyl transferase in nigerian diabetics: possible clinical implications. 17004039 - The role of exogenous insulin in the complex of hepatic lipidosis and ketosis associate... 14981219 - Weight cycling and the risk of developing type 2 diabetes among adult women in the unit... 14741069 - Insulin glargine: long-acting basal insulin analog for improved metabolic control. 21992869 - Educational attainment moderates the effect of a brief diabetes self-care intervention. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-10-19 |
Journal Detail:
|
Title: Clinical therapeutics Volume: - ISSN: 1879-114X ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7706726 Medline TA: Clin Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved. |
Affiliation:
|
Ossian Health Economics and Communications GmbH, Basel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myo...
Next Document: Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavul...